Abstract
We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial. After complete transurethral resection of Ta–T1 G1–G2 transitional cell bladder carcinomas, patients were treated with mitomycin 40 mg/50 ml saline of 15 instillations for 12 months. Most of the complications were mild and transient but two patients dropped out of the trial because of moderate side effects. Fifty-one patients were evaluable. We observed tumour recurrences in six patients (11.8%) during a median follow-up of 44.5 months. The recurrences were treated by transurethral resection. There was no muscle invasive progression in the recurrences. Our investigations confirm the effectiveness of mitomycin C in the treatment of patients with superficial bladder cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aeikens, B., Niermann, R., Schindler, E.: Investigation about the penetration depth in the normal bladder wall and tumour by local instillation of mitomycin into the urinary bladder. Urol. Int., 37, 389 (1982).
Akaza, H., Kurth, K. H., Williams, R., Hinotsu, S., Jewett, M. A. S., Naito, K., Okada, K., Schellhammer, P. F., van Velthoven, R. F., Witjes, J. A.: Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction. Urologic Oncology, 4, 121 (1998).
Beretta, G.: Mitomycin C: Current Status. Edizioni Minerva Medica, Turin 1996, pp. 97–100.
Farrow, C. M., Utz, D. C., Rife, C. C.: Morphological and clinical observation of patients with early bladder cancer treated with total cystectomy. Cancer Res., 36, 2495 (1976).
Flüchter, S: H., Harzmann, R., Bichler, K. H.: Local mitomycin C therapy of transitional cell carcinoma of the bladder — serum resorption study and clinical results. In: Ogawa, M., Rozencweig, M., Staquet, M. J. (eds): Mitomycin C. Current Impact on Cancer Chemotherapy. Excerpta Medica, Amsterdam 1982, p. 143.
Imperial Cancer Research Fund: Cancer Statistics Fact Sheet (May 1995).
Kurth, K. H. et al.: Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer, 31A, 1840 (1995).
Lamm, D. L., Griffith, J. G.: The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes). Prog. Clin. Biol. Res., 378, 43 (1992).
Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. North Am., 19, 573 (1992).
Lamm, D. L., van der Meijden, A. P. M., Akaza, H. et al.: Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int. J. Urol., 2(Suppl. 2), 23 (1995).
Lown, J. W.: The molecular mechanism of antitumor action of mitomycins. In: Carter, S. K., Crooke, S. T., Alder, N. A. (eds): Mitomycin C: Current Status and New Developments. Academic Press, New York 1979, p. 5.
Pawinski, A. et al.: A combined analysis of EORTC and MRC clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J. Urol., 156, 1934 (1996).
Soloway, M. S., Masters, S.: Urothelial susceptibility to tumor cell implantation. Influence of cauterization. Cancer, 46, 1158 (1980).
Tolley, D. A., Parmar, M. K. B., Grigor, K. M., Lallemand, G. and The Medical Research Council Superficial Bladder Cancer Working Party: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of followup. J. Urol., 155, 1233 (1996).
Vegt, P. D: J., Witjes, J. A., Witjes, W. P. J., Doesburg, W. H., Debruyne, F. M. J., van der Meijden, A. P. M.: A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol., 153, 929 (1995).
Wajsman, Z., Dhafir, R. A., Pfeffer, M., MacDonald, S., Block, A., Dragone, N., Pontes, E.: Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors. J. Urol., 132, 30 (1984).
Witjes, J. A.: Superficial bladder cancer, including T1G3 disease. Eur. Urol., 34/2 (Curric. Urol. 6.2: 1–6) (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kondás, J., Kiss, L., Határ, A. et al. The Effect of Intravesical Mitomycin C on the Recurrence of Superficial (Ta–T1) Bladder Cancer. A Hungarian Multicenter Study. Int Urol Nephrol 31, 451–456 (1999). https://doi.org/10.1023/A:1007155026151
Issue Date:
DOI: https://doi.org/10.1023/A:1007155026151